Persistent’s long growth streak is meeting a fundamentally different business in Nagarro—and investors must value the financing, cash restrictions and slower acquired growth.
What Happened on 16 October?
16 OCT CLOSE
₹5,741
−1.70% session
PERSISTENT Q2 SALES
₹4,663.9cr
+30.3% in INR
REPORTED Q2 PAT
₹351.5cr
operating PAT ₹495.2cr
NAGARRO H1 ORGANIC CC
+2.7%
target filing
*Market return and volume from secondary trading records; financing authorisations are not executed funded debt. Financial data is company-reported. All prices reflect the 16 Oct 2026 dated evidence, not a live quote.
A tech-services company with 26 consecutive quarters of revenue growth is buying scale from a business growing much more slowly. The transaction may widen its geographic and capability moat—but only if the profits and cash created exceed the capital and complexity required to buy them.
An extraordinary operating franchise faces a new capital testPersistent reported Q2 revenue of ₹4,663.9 crore (+30.3% YoY in rupees) and $487.6 million of USD revenue. It also recorded its 26th consecutive quarter of USD revenue growth. Shares closed at ₹5,741 on 16 October, down approximately 1.70%, as investors absorbed results and its acquisition plans.
Profit headlines require reconciliationReported Q2 PAT was ₹351.5 crore, down 25.4% YoY, versus management-defined operating PAT of ₹495.2 crore. The ₹143.6 crore gap includes acquisition-related adjustments, which should not be annualised but do represent real transaction economics.
The target has a different growth trajectoryNagarro’s own H1 CY26 release shows organic constant-currency revenue growth of only 2.7%, versus Persistent’s much faster legacy expansion. A merger does not automatically raise the acquired business’s growth rate to the buyer’s historic level.
Persistent’s Q2 USD revenue +20%, Nagarro H1 organic CC growth +2.7%, and an unsettled ~$1.25bn funding plan.
Original company filings [P1] ↗[P2] ↗. Price references remain secondary until exchange reconciliation.
Why Did It Happen—and Who Actually Earns?
Persistent sells differentiated platform engineering, cloud/data modernisation and industry-specific software services. Its customer context and execution track record are valuable precisely because they take years to build. Nagarro adds European access and engineering capacity—but the value created by scale must be earned through contracts and cash, not simply combined in a slide. Buying a billion-euro revenue business is not equivalent to creating a billion euros of high-return incremental sales.
01Own the customer relationshipPersistent high-growth engineering accounts→
02Acquire a different engineNagarro’s client base, employees and legacy economics→
03Finance and integrateTender consideration, debt, issuance, fees and PPA→
04Deliver per-share cashSynergies minus interest, dilution, tax and reinvestment
The financing structure matters almost as much as the target. Persistent discussed up to $1.25 billion of combined equity/debt capacity, including up to $450 million of equity. Authorised debt or bonds are not the same as funded loans, and management’s ~1.7× leverage illustration is not a completed-balance-sheet fact. Final deal cash, issue price, refinancing coupon, target liabilities and German legal restrictions determine shareholder value after closing.
Price vs News Timeline
What preceded the market reaction?
€81/share voluntary tender and a complex German takeover path.
Approximately 83.25% shares secured through accepted or contracted blocks.
94.04% secured; regulatory approval and legal closing still pending.
Q2 FY27 results and later press reporting on proposed NCD/refinancing; authorisation ≠ funded debt.
Does the narrative match the numbers?
Market move on 16 October: -1.70% · secondary-market record
PressureUnresolvedConfidence
This spectrum is an editorial interpretation, not a measured sentiment index. Price causality cannot be established from one session.
Persistent CC growth
+20.8%
Nagarro H1 organic CC
+2.7%
The Financial Evidence Behind the Headline
Historical operating performance
Historical company data
Source: dated company financial presentations and relevant original filings. This is an operating comparison, not a live share-price series.
Financial bridge: what actually changed?
| Indicator | Reported movement |
|---|---|
| Persistent Q2 reported PAT | ₹351.5cr |
| Management operating PAT | ₹495.2cr |
| Nagarro organic CC growth | +0.6% Q2 |
| Target H1 cash flow | €29.5m |
Driver-led FY27–FY29 house case
| Period | Revenue ₹cr | Margin | PAT ₹cr | FCF ₹cr | ROCE |
|---|---|---|---|---|---|
| FY27E | 18,500 | 14.8% | 1,952 | 1,659 | 20.3% |
| FY28E | 32,700 | 14.3% | 2,905 | 2,034 | 17.3% |
| FY29E | 38,500 | 15.0% | 3,645 | 3,098 | 18.6% |
Analyst scenario forecasts (FC), not management guidance. ROCE uses company-specific capital assumptions and may not be comparable across an IT company and a manufacturing company.
What Is the Market Saying?
Evidence supporting the story
- ✓
Legacy delivery is exceptional26 consecutive sequential USD-revenue growth quarters and strong customer-engineering positioning.
- ✓
Geographic logic has substanceA larger European platform could widen account access and engineering delivery scale.
- ✓
The deal has achieved meaningful acceptance94.04% of Nagarro shares were reported secured by 9 October; it is not yet equivalent to legal closing.
What could change the narrative?
- !
Nagarro’s organic growth is much slowerH1 CY26 organic CC +2.7%; Q2 CY26 organic CC +0.6%, according to its own earnings release.
- !
Closing financing is not fully settledDebt draw, equity dilution, purchase price allocation and bond coupon are not final economic facts.
- !
Cash is legally and operationally complexTarget operating CFO fell in H1; post-close upstreaming may face restrictions requiring German legal diligence.
The deal could improve the competitive franchise and still dilute near-term cash returns if financing, integration and dilution exceed the target’s earnings contribution. The right scorecard begins at legal close, using the full consideration and true capital employed.
The Earnings the Share Price Requires
Three scenarios. One earnings engine.
Explore the illustrative FY29 economics behind our house case. Change revenue, margin or terminal P/E to see the return sensitivity. These are analytical forecasts—not price targets, trading recommendations or company guidance.
FY29 revenue (₹cr)
EBIT margin (%)
Depreciation (₹cr)
Net finance / non-operating (₹cr)
Effective tax (%)
Diluted shares (crore)
Exit P/E (×)
FCF / PAT (%)
—
FY29 earnings / share—
Price CAGR · 3 years—
FY29 FCF—
18% hurdle price—
—
EPS required for 18% at selected exit multiple: —
Based on 5741 reference share price and a 3-year annualised horizon. FY29 PAT = (operating revenue × operating margin − company-specific depreciation and net financing) × (1 − modelled tax). EPS uses a fixed assumed share count; dilution, timing, capital actions and dividends can alter outcomes. For Tech Mahindra EPS and share price use the pre-bonus basis. *Market return and volume from secondary trading records; financing authorisations are not executed funded debt.
What to Watch Next
CLOSING · Q4 CY26 / Q1 CY27
Actual stake, net price, acquired cash/debt, financing draw, new equity, PPA and legal restrictions.
FIRST FOUR QUARTERS
Separately publish legacy organic growth, Nagarro organic growth, costs, synergies and cash after debt service.
FY28–FY29
Positive EPS and FCF per fully diluted share with demonstrably attractive incremental ROCE.
Questions management must answer
- What is the final all-in purchase enterprise value including acquired liabilities and completion adjustments?
- What is the post-close interest, minority-rights and issued-share bridge per surviving Persistent share?
- Will cross-sell and synergies produce cash earnings above acquisition WACC by FY29?
What would falsify the case?
- Final funded leverage materially above illustrative ~1.7× mix
- Nagarro organic growth stagnates and cross-sell fails
- Persistent equity dilution or financing cost significantly exceeds model
- Cash cannot be upstreamed as expected / integration delays
- FCF conversion persistently below ~60%
Publication gate / material evidence gaps: Final takeover financing and actual issued shares; Acquired balance sheet, PPA, goodwill and amortisation; Legal opinion on German upstreaming limitations; Independent integration synergies and customer overlap. No definitive claim should rest on these items without corroboration.
Forensic reading: the numbers below the headline
INVESTIGATIVE DESK · COMPANY-SPECIFIC EXPANDED EDITION
Persistent’s Q2 USD revenue grew 20.0% and its 26-quarter growth streak continued, yet reported PAT contracted 25.4%. The business story is no longer just digital-engineering compounding: the Nagarro transaction introduces purchased revenue, acquisition funding, amortisation, minority rights, and materially weaker target organic growth.
AS OF: 16 October 2026 cutoffReported ≠ adjusted ≠ forecastIndependent corroboration identifiedPublish-gate in progress
01 / How the business actually earns money
The mechanism the headline cannot explain
Legacy earnings versus deal expenses
Reported Q2 PAT ₹351.5cr compared with company operating PAT ₹495.2cr. The ₹143.7cr gap arises from the company’s adjustment framework and cannot simply be deleted from shareholder economics; transaction-related expenditure still represents a real acquisition cost.
Target is a different business
Nagarro H1 CY26 revenue €500.5m was +0.3% YoY in euros, +4.2% CC but only +2.7% organic CC. Adjusted EBITDA improved to 13.8%, while CFO fell from €42.4m to €29.5m and gross debt was ~€310.5m.
Tender control is not closing
Persistent said it secured about 94.04% of voting capital after the tender period, but closing is expected by Q1 CY27 and minority squeeze-out remains subject to process. Forecasting a full FY27 acquired year would overstate recognised earnings.
Independent cross-check / limits of what it proves. Nagarro’s own August 14 statement provides genuine independent target-company evidence: 2.7% organic H1 constant-currency growth, €69.1m H1 adjusted EBITDA and €29.5m operating inflow. This is stronger corroboration than merely repeating the acquirer’s synergy slides. The target’s DSO remained ~86 days and loans were €310.5m.
02 / Where the accounting and cash diverge
Reported-to-normalised operating bridge
| Metric | Observation | Interpretation and scope |
|---|---|---|
| Q2 USD sales | $487.6m | +20.0% YoY; +7.8% QoQ |
| Q2 EBIT | ₹697.7cr | 15.0% EBIT margin |
| Company operating PAT | ₹495.2cr | +5% YoY, excludes specified items |
| Reported Q2 PAT | ₹351.5cr | −25.4% YoY |
| Company adjustment gap | ₹143.7cr | Operating less statutory PAT, not “free money” |
| Nagarro H1 organic CC growth | +2.7% | Target revenue growth lower than legacy |
| Nagarro H1 CFO | €29.5m | from €42.4m prior |
| Shares secured | 94.04% | Tender outcome; not completed closing |
The FY29 forecast assumes 16.55cr diluted shares versus ~15.775cr historic; this illustrative 4.9% dilution must be refreshed after the actual financing. Acquired balance sheet, cash and borrowing cannot be counted twice.
03 / The dated event tape
Price, news and what came first
Market reference: ₹5,741 · −1.70% · secondary closing record. Source: dated company or market evidence ↗. The timeline below does not invent an unverified daily price/volume series, abnormal delivery statistic or minute-level causal attribution.
Nagarro H1 operating results — 2.7% organic CC growth; CFO €29.5m
First tender outcome — 83.25% secured, additional period opened
94.04% tender acceptance announced — Not final legal closing
Persistent Q2 results — USD sales +20%, statutory PAT −25.4%
Shares ease approximately 1.70% — Do not attribute every tick exclusively to Nagarro
04 / Accountability and counterevidence
What management has—and has not—proved
Acquirer commentary envisages a larger AI-powered digital-engineering franchise. The value test is the incremental post-tax cash operating profit generated by Nagarro plus realised synergies, net of interest, PPA amortisation, integration cost and capital put into purchased goodwill. Growth inherited from acquisition cannot be relabelled legacy organic expansion.
| Test | Evidence status | Necessary next proof |
|---|---|---|
| Persistent statutory and adjusted PAT | Verified company Q2 release | Adjustment labels disclosed |
| Nagarro H1 growth & cash | Independent target company release | Different calendar periods / scope |
| 94.04% tender outcome | Acquirer filing dated 9 Oct | Closing still expected Q1 CY27 |
| Financing and purchase allocation | Partially disclosed proposals | Final funding mix, PPA and dilution not settled |
Disconfirming condition. Acquired organic revenue stays near zero; target DSO remains elevated; synergy announcements outrun actual EBIT/FCF; financing pushes share count or interest above model; incremental operating ROCE after goodwill is below the cost of capital.
05 / The shareholder equation
Annual FY27–FY29 underwriting, not an isolated target price
Inputs below start from the dated ARDEKO house model, not management guidance. Edit growth, profit margins, cash realisation and exit multiples. The FY29 return calculation uses the approximately 2.46-year interval from October 2026 to March 2029; no dividends are credited. The adjustments are transparent sensitivities, not a rebuilt three-statement DCF.
Interactive EPS / terminal P/E and cash conversion laboratory
House Base · working-case controls · each output updates instantly · ₹cr and pre-corporate-action ₹/share
Revenue / book growth overlay (%)
EBITDA / EBIT margin delta (pp)
FCF realisation vs model (%)
Terminal P/E multiple
FY29 implied share—
Annualised return—
18% hurdle price—
FY29 FCF proxy—
Risk: The cash-realisation input is linked to projected FCF, while exit prices use the selected earnings/book multiple. A high P/E alongside low FCF conversion should be treated as a thesis-quality warning, not silently assigned a lower mathematical multiple. For bank book valuation, industrial FCF is deliberately not shown.
06 / Source-level provenance
Original documents—not just a source list
Use original filings for figures, dated releases for management statements and separate market sources for exchange reactions. Financials, calendar periods and consolidation perimeter should match before comparing ratios. Each material unavailable field remains an explicit publication blocker rather than a guessed value.
↗ Persistent Q2 FY27 official resultsOriginal acquirer earnings and adjustments↗ Persistent Q2 statement archiveOriginal financials↗ Persistent tender outcome, 9 OctControl versus close timeline↗ Nagarro H1 2026 original releaseIndependent target economics↗ Nagarro FY25 annual reportTarget risk and cash history
↓ Read full investigative PDF← All six MoneyMeister stories
Publication status: Internal investigative research edition · market cutoff 16 October 2026 · signed/original documents, final capital treatment and independent peer/customer checks may still be incomplete. No claim of exhaustive NSE/BSE coverage. Forecast assumptions are not guidance.
Original Documents and Source Trail
Exchange filings and company IR documents support reported financial claims. Company aspirations are treated as management statements; models as forecasts; valuation interpretation as ARDEKO inference. Secondary price records are explicitly caveated.
Document links are external and may change or become unavailable. The full technical reconstruction and detailed references are preserved in the ARDEKO research master PDF ↗.